Professional Documents
Culture Documents
Haemorrhage 24%
Other direct 6%
PPH 17%
Anaemia 4%
Eclampsia 21%
Low uterotonic coverage (Oxytocin or Misoprostol) Low SBA retention in remote areas
Abortion 7%
Sources: Nepal Demographic and Health Surveys, 2006, 2011; Maternal Mortality and Morbidity Survey 2008/09
Basic research
Regional RCT showing efficacy
Pilot in Context
First priority was to increase skilled attendance at birth and institutional deliveries through:
Health facility upgrades Emphasis on AMTSL at health facilities SBA in-service training Maternity incentive scheme
Misoprostol distribution by FCHVs for prevention of PPH at home birth within a broader community approaches
At 8th month, FCHVs distributes Misoprostol. During PNC home visits confirms use and retrieves if unused
Delivery
Danger signs and referral
Danger signs and referral Promotion of institutional deliveries Essential newborn care
Post-natal
Danger signs and referral (including neonates) Birth weight
ENC Exclusive breast feeding PNC (rest, food, hygiene, etc.) Family Planning Iron/folate Post-natal Vit A
Counsel
Birth preparedness and complication readiness Danger signs/refer Seeking care, TT & antihelminthic Rx Misoprostol Iron/folate Misoprostol BPP action card
Distribute
Document
Pregnancy registration
Pregnancy outcomes
100 80 60 40 20 0
86
Percent
14 0
afer the delivery of the babybut before the delivery of the placenta
Symptoms Reported
100 90 80 70 60 50 40 30 20 10 0
27 22 18.5 15.1 3.4 6.2 9 9.4 2 1.3 6.3 7
Percent
Used MSC
Headache
Shivering
Nausea
Loose motion
Dizzy
Fever
Uterotonic Coverage
100 80
60
40
20
Endline
Policy considerations Mar 2010: Nepal country team committed for national level expansion of MSC (Reconvening BKK conference) Pilot Regional RCT used for advocacy April/May 2010: Sharing and advocacy at the national level June 2010: MOHP approved for national level expansion July 2010: Developed implementation guidelines
6 months: pilot results to scaleup Pilot results used to demonstrate feasibility Influential evidence
Progression to scale
Use of uterotonic drugs: Inj. Oxytocin within a minute after delivery of baby
Uterine massage
Use of uterotonic drug: Tab Misoprostol (600 mcg) after delivery of a baby
N
Mid-Western Region
Dadeldhura Doti
Western Region
Central Region
Eastern Region
Solukhumbu Sankhuwasava Taplejung
Legend
Pilot 2005 Expansion 2009/10 Expansion 2010/11 Plan for Expansion 2011/12
Ilam
GoN is committed to increase uterotonic coverage (GON expanding the intervention and purchasing Misoprostol) Priority is AMTSL during deliveries at health facilities Misoprostol national level scale-up focusing in remote areas.
28
Misoprostol coverage
HW/HF delivery
Source: District HMIS, 2011/12
Conclusions
National context: Urgent need to reduce MMR due to PPH Realistic piloting under MoHP system Rapid move from pilot to scaleup (<2 years) Consensus and support from all stakeholders (including Nepal Society of Ob/Gyns) for scale-up Nepal is pioneer in successful implementation of Misoprostol and has been a subject of global interest
Challenges
Distribution of misoprostol, ensuring availability and transportation Collection of reports from grassroots level Program expansion/coverage only in partners supported districts limiting the expansion in priority districts Ensuring the quality of training to FCHVs
Thank You
Implementing Partners Government of Nepal (FHD lead) Partners
USAID/NFHP II and its partners UNICEF CARE Nepal Rural Health Development Program (RHDP)/SDC Health Right International Nepal Society of Obstetricians and Gynaecologists (NESOG) One Heart Worldwide (planning to support in expansion)